What Corporate Venture Funds Get Wrong about Strategic Value
Corporate venture funds often chase financial returns while ignoring strategic value. Here’s what it takes to turn healthcare portfolio investments into lasting business impact.
David M. Rubin
David M. Rubin, Ph.D., is a Managing Director in Merck GHIF, where he leads the drug discovery and precision medicine practice. Dr. Rubin ran and helped build life sciences companies in the USA, UK, Denmark, Hungary, and India. He was awarded National Institutes of Health and American Cancer Society Fellowships to support his research at Harvard Medical School on ubiquitin-dependent protein degradation. He received a B.A. in biology from SUNY Binghamton and a Ph.D. from Temple University. Junk Birds, his collection of previously published short stories, was published in 2025.